TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05677282

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifaximin 550 MG
Description: Rifaximin 550 mg as a single dose administered orally.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Azithromycin 500 MG
Description: Azithromycin 500 mg as a single dose administered orally.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Loperamide
Description: 4 mg loperamide administered orally with study antibiotic (rifaximin or azithromycin). Additional loperamide to use as needed, but not to exceed 16 mg/day for 2 days as per licensed use (one 2 mg capsule after each looses stool).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Loperamide
Description: 4 mg loperamide administered orally with study antibiotic (rifaximin or azithromycin). Additional loperamide to use as needed, but not to exceed 16 mg/day for 2 days as per licensed use (one 2 mg capsule after each looses stool).
Study: NCT06114888

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: MeMed BV + Usual Care
Description: We will aim to have blood drawn for MeMed BV testing within 24 hours of the first dose of IV antibiotics. We will then aim to have test results back within 24 hours of sampling.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care Alone
Description: Usual care can involve oxygenation support, ventilatory support, intravenous fluids, and antibiotics, or any combination of these.
Study: NCT05213702

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Renal Calyx punture with traditional free hand or ANT-X device
Description: ANT-X device is a software-controlled automated electromechanical arm. It is developed to provide needle guidance for surgeon in MIS. This aims to reduce the surgery time taken and also minimize the radiation withstand by both surgeon and patient. ANT-X device is actually a Delta parallel robot implementing inverse kinematics to achieve effector's movement. Parallel structures excel in their great stiffness and high positioning accuracy. Most of the main components of ANT-X robot are made up of medical grade Polyether ether ketone (PEEK) material. PEEK is preferred to build the robot because it is radiolucent and lightweight while being able to provide relatively high material strength. The device is intended for use together with C-arm fluoroscope (fluoroscopy/CT technology). The fluoroscopy technology is used to provide image guidance for the needle

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Renal Calyx punture with traditional free hand or ANT-X device
Description: ANT-X device is a software-controlled automated electromechanical arm. It is developed to provide needle guidance for surgeon in MIS. This aims to reduce the surgery time taken and also minimize the radiation withstand by both surgeon and patient. ANT-X device is actually a Delta parallel robot implementing inverse kinematics to achieve effector's movement. Parallel structures excel in their great stiffness and high positioning accuracy. Most of the main components of ANT-X robot are made up of medical grade Polyether ether ketone (PEEK) material. PEEK is preferred to build the robot because it is radiolucent and lightweight while being able to provide relatively high material strength. The device is intended for use together with C-arm fluoroscope (fluoroscopy/CT technology). The fluoroscopy technology is used to provide image guidance for the needle
Study: NCT05699824

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carvedilol Day2
Description: Carvedilol will be initiated on day 2, at a dose of 3.125mg twice a day (6.25mg/day), along with standard management as per institutional protocol for AVB.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard Medical Treatment
Description: All patients to receive Inj. Terlipressin, 1 mg at 4 hours along with standard management for acute variceal bleed as per institutional protocol. Standard Medical Treatment

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Medical Treatment
Description: All patients to receive Inj. Terlipressin, 1 mg at 4 hours along with standard management for acute variceal bleed as per institutional protocol. Standard Medical Treatment

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carvedilol Day6
Description: Carvedilol will be initiated on day 6, at a dose of 3.125mg twice a day (6.25mg/day), along with standard management as per institutional protocol for AVB.
Study: NCT05181644

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EmoLED treatment
Description: Treatment with the EmoLED device consists of irradiating each area of 5 cm in diameter of the lesion for 60 seconds; if the lesion is larger than 5 cm in diameter, the applications will be repeated up to cover the entire area of interest. EmoLED treatment is additional to the standard therapy for the patient.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: current Standard of Care
Description: The acral lesions will be cleansed with physiological solution, disinfected with a special device and, if necessary, a debridement will be carried out with the most appropriate method.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: current Standard of Care
Description: The acral lesions will be cleansed with physiological solution, disinfected with a special device and, if necessary, a debridement will be carried out with the most appropriate method.
Study: NCT05766826

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Coupons for safe water program: Treatment
Description: Randomly selected women in the treatment group will receive coupons for free chlorine solutions to be redeemed at the health facility each month.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Coupons for safe water program: Control
Description: Randomly selected women in the treatment group will not receive coupons for free chlorine solutions after enrollment.
Study: NCT05270837

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegvaliase
Description: Pegvaliase 2.5mg/10mg/20mg/40mg/60mg self-administered from 1 time up to 7 times a week

Intervention type: OTHER
Group type: OTHER
Intervention: Diet Only
Description: Diet Control
Study: NCT04120415

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Vaccine and vedolizumab (Entyvio)
Description: Vaccine and vedolizumab infusion (Entyvio):~0.5ml of MVA HIV-B (1 x 108 pfu/ml) will be administered intramuscularly in the deltoid muscle of the non-dominant upper arm at weeks 0 and 8. Participants will be observed after the injection.~Vedolizumab (300mg) is administered as an intravenous infusion (255 ml) over 30 mins in the dominant arm at weeks 10,12,16,20,24,28 and 32. After infusion, the line should be flushed with 30ml of normal saline. Participants will be observed throughout and after the infusion.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo vaccine and vedolizumab infusion (Entyvio)
Description: Placebo Vaccine:~The placebo for MVA HIV-B to be used is a solution composed of S08 buffer (as for the MVA vaccine) that will be intramuscularly in the deltoid muscle of the non-dominant upper arm at weeks 0 and 8. Participants will be observed after the injection.~Vedolizumab infusion (Entyvio):~Vedolizumab (300mg) is administered as an intravenous infusion (255 ml) over 30 mins in the dominant arm at weeks 10,12,16,20,24,28 and 32. After infusion, the line should be flushed with 30ml of normal saline. Participants will be observed throughout and after the infusion.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo vaccine and placebo infusion
Description: Placebo Vaccine:~The placebo for MVA HIV-B to be used is a solution composed of S08 buffer (as for the MVA vaccine) that will be intramuscularly in the deltoid muscle of the non-dominant upper arm at weeks 0 and 8. Participants will be observed after the injection.~Placebo infusion (Entyvio):~255ml Sodium Chloride (NaCl) 0.9% bag administered as an intravenous infusion over 30 mins in the dominant arm at weeks 10,12,16,20,24,28 and 32. Participants will be observed throughout and after the infusion.
Study: NCT05809193

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Family-Focused Therapy
Description: After the patient and family are informed, they are included in the therapy group on a voluntary basis. After evaluation by independent evaluators, therapy sessions are started by therapists.~Session 1: Goal Setting, Treatment Overview, Symptoms, Vulnerability Stress Model Session 2: Stress and Coping Skills, Regulation of sleep habits, Relaxation exercises Session 3: Optimizing Family Support; Prevention Plan, Medication adherence Session 4: Overview of Communication Skills; Expressing Positive Feelings, Active Listening Session 5: Making Positive Requests for Change, Communication Clarity Session 6: Expressing Negative Feelings Session 7: Introduction to Problem Solving Skills Session 8 and 9: Problem Solving Skills, Termination of Treatment The same psychometric assessment will be repeated before and after FFT. Intra-group comparisons will be made. Also study groups will be compared using time by group interactions to investigate the differences in therapy response.
Study: NCT05021770

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Orelabrutinib
Description: 150mg or 200mg orally daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Orelabrutinib
Description: RP2D

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thiotepa
Description: 30 mg/m2 intravenously every 3 weeks (maximum 6 cycle)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thiotepa
Description: 30 mg/m2 intravenously every 3 weeks (maximum 6 cycle)
Study: NCT04248127

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Honey sweetened yogurt
Description: 2 tbsp. of daily honey intake in 1.2 cups of yogurt per day, split into two equal portions

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Sugar sweetened yogurt
Description: sugar added, in an isocaloric fashion to the honey, to 1.2 cups of yogurt per day, split into two equal portions
Study: NCT04880655

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: WSD
Description: Post debridement and within 24 hours of injury, wound care and WSD applied daily

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Dressed with bacitracin and petrolatum gauze
Description: Post debridement and within 24 hours of injury, wound care and dressing applied daily
Study: NCT05439356

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Colchicine
Description: Oral colchicine will be initiated with a dose of 1mg per day (one tablet of 0.5mg initially followed by another tablet of 0.5 mg at least four hours later) on days 1 through 3, and continuing with 0.5 mg (one tablet) per day on days 4 through 90.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo colchicine
Description: Oral placebo colchicine will be initiated with a dose of 1mg per day (one tablet of 0.5mg initially followed by another tablet of 0.5 mg at least four hours later) on days 1 through 3, and continuing with 0.5 mg (one tablet) per day on days 4 through 90.
Study: NCT06471218

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-1918; SHR-1918 Placebo
Description: SHR-1918/SHR-1918 Placebo,two administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-1918; SHR-1918 Placebo
Description: SHR-1918/SHR-1918 Placebo,two administration
Study: NCT06073652

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control 1st age starter infant formula
Description: A standard bovine milk-based term infant formula.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental 1st age starter infant formula
Description: Same content as Control formula plus supplemented with a HMO blend and a probiotic
Study: NCT05018715

Intervention type: DIAGNOSTIC_TEST
Intervention: Machine learning model diagnosis
Description: Machine learning model diagnosis
Study: NCT05851144

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Bienestar/Neema Coordinated School Health Program (BN CSHP)
Description: Bienestar/Neema Coordinated School Health Program (BN CSHP), a Texas Education Agency-approved school health curricula, is a multi-prong intervention
Study: NCT06261515

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Active periodontal treatment
Description: Subgingival instrumentation with ultrasonic devices and curettes of all periodontal pockets; periodontal surgery if needed (residual probing pocket depths ≥ 6 mm).
Study: NCT03158857

Intervention type: DRUG
Intervention: Sofosbuvir 400 mg
Description: These drugs are being offered as part of routine care

Intervention type: DRUG
Intervention: Sofosbuvir 400 mg
Description: These drugs are being offered as part of routine care
Study: NCT05850156

Intervention type: PROCEDURE
Intervention: basal blood collection
Description: blood collection is performed in the context of routine care for hemoglobin analysis. An additional volume of 300µL of blood is taken for the purposes of the study

Intervention type: PROCEDURE
Intervention: basal blood collection
Description: blood collection is performed in the context of routine care for hemoglobin analysis. An additional volume of 300µL of blood is taken for the purposes of the study

Intervention type: PROCEDURE
Intervention: basal blood collection
Description: blood collection is performed in the context of routine care for hemoglobin analysis. An additional volume of 300µL of blood is taken for the purposes of the study

Intervention type: PROCEDURE
Intervention: basal blood collection
Description: blood collection is performed in the context of routine care for hemoglobin analysis. An additional volume of 300µL of blood is taken for the purposes of the study

Intervention type: PROCEDURE
Intervention: blood collection M6
Description: 6 months +/- 2 months after inclusion, a blood collection is performed in the context of routine care for hemoglobin analysis. An additional volume of 300µL of blood is taken for the purposes of the study

Intervention type: PROCEDURE
Intervention: blood collection M6
Description: 6 months +/- 2 months after inclusion, a blood collection is performed in the context of routine care for hemoglobin analysis. An additional volume of 300µL of blood is taken for the purposes of the study

Intervention type: PROCEDURE
Intervention: blood collection M12
Description: 12 months +/- 2 months after inclusion, a blood collection is performed in the context of routine care for hemoglobin analysis. An additional volume of 300µL of blood is taken for the purposes of the study

Intervention type: PROCEDURE
Intervention: blood collection M12
Description: 12 months +/- 2 months after inclusion, a blood collection is performed in the context of routine care for hemoglobin analysis. An additional volume of 300µL of blood is taken for the purposes of the study
Study: NCT06123884

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant humanized anti-PD-1 monoclonal antibody injection
Description: Strength 100 mg/4 mL, intravenous drip, recommended dose 300 mg, administered every 3 weeks (21 days) (Q3W).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Recombinant humanized anti-PD-1 monoclonal antibody injection
Description: Strength 100 mg/4 mL, intravenous drip, recommended dose 300 mg, administered every 3 weeks (21 days) (Q3W).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: the usage and dosage should be determined by the investigator

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cisplatin
Description: the usage and dosage should be determined by the investigator

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab Injection
Description: Strength 100 mg/4 mL, recommended dose 15 mg/kg body weight, administered every 3 weeks (15 mg/kg, Q3W)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Bevacizumab Injection
Description: Strength 100 mg/4 mL, recommended dose 15 mg/kg body weight, administered every 3 weeks (15 mg/kg, Q3W)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: the usage and dosage should be determined by the investigator

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: carboplatin
Description: the usage and dosage should be determined by the investigator

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel for Injection
Description: the usage and dosage should be determined by the investigator

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Paclitaxel for Injection
Description: the usage and dosage should be determined by the investigator
Study: NCT04787575

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Oxygen-ozone therapy
Description: Oxygen-ozone therapy (group a) will be performed by:~i) Self-haemoinfusion of 200 cc. with concentrations of 40-50 μg/ml, to be performed two/three times a week, for a time of 6 weeks (for a maximum of 15 sessions); ii) Subcutaneous injections in the perilesional site at the dose of 5 cc. with concentrations of 4 μg,/ml, Cleanse wounds with 100 cc of 5-10 ug ozone gas

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Oxygen-ozone therapy
Description: Oxygen-ozone therapy (group a) will be performed by:~i) Self-haemoinfusion of 200 cc. with concentrations of 40-50 μg/ml, to be performed two/three times a week, for a time of 6 weeks (for a maximum of 15 sessions); ii) Subcutaneous injections in the perilesional site at the dose of 5 cc. with concentrations of 4 μg,/ml, Cleanse wounds with 100 cc of 5-10 ug ozone gas
Study: NCT04446182

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itacitinib
Description: All eligible patients will begin study therapy with approximately a week lead-in of itacitinib monotherapy at scheduled dose. Itacitinib will be taken daily at scheduled dose for a total of six cycles. Itacitinib may be tapered as deemed appropriate by the treating investigator. Patients will remain on study therapy as long as treatment discontinuation criteria are not met. Patients with Partial Response (PR) or better may continue itacitinib for up to 1 year.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Extracorporeal Photopheresis (ECP)
Description: ECP will begin after itacitinib lead in period. At the end of 8 weeks of combination therapy, patients will start a standard ECP taper schedule. Patients achieving PR or better after 6 cycles of itacitinib may continue treatment with itacitinib for up to 1 year. Thereafter, itacitinib may be tapered at the treating investigator's discretion.
Study: NCT04629209

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ONC201
Description: ONC201 is a orally active, small molecule DRD2 antagonist that kills cancer cells but not normal cells.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ONC201
Description: ONC201 is a orally active, small molecule DRD2 antagonist that kills cancer cells but not normal cells.
Study: NCT05338749

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Training
Description: Gamified cognitive training intervention to improve mental speed and attention.
Study: NCT05602558

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LYB001
Description: The antigen consists of receptor-binding domain (RBD) from wild-type SARS-CoV-2 displaying on virus-like particle (VLP) vector, adjuvanted with aluminium hydroxide.
Study: NCT05318027

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ChatBot
Description: The automated chatbot will check in with the patient on two pre-specified days between scheduled outpatient visits. The chatbot will follow pre-specified symptom algorithms and classify symptoms as requiring high, intermediate and low risk follow ups. High risk symptoms will trigger a same day nursing/physician visit or telemedicine call/video. Intermediate risk symptoms will trigger a nursing triage visit or telemedicine call/video on the next day or treatment day. Low risk symptoms will notify the treating physician to address the symptoms at the next scheduled on treatment visit (OTV). If adjustments are needed in the chat bot triage algorithms, they will be updated in real time to decrease risk for adverse patient events.
Study: NCT06195137

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Caffeine
Description: caffeine supplementation

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Alpha Lipoic Acid
Description: 600-800 mg ALA
Study: NCT05074368

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: ChAdOx1-nCov-19 (Astra-Zeneca)
Description: vaccine inoculation and mixed inoculation

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: ChAdOx1-nCov-19 (Astra-Zeneca)
Description: vaccine inoculation and mixed inoculation

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: ChAdOx1-nCov-19 (Astra-Zeneca)
Description: vaccine inoculation and mixed inoculation

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: ChAdOx1-nCov-19 (Astra-Zeneca)
Description: vaccine inoculation and mixed inoculation

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: SARS-CoV-2 messenger RNA-1273 (Moderna) vaccine
Description: vaccine inoculation and mixed inoculation

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: SARS-CoV-2 messenger RNA-1273 (Moderna) vaccine
Description: vaccine inoculation and mixed inoculation

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: SARS-CoV-2 messenger RNA-1273 (Moderna) vaccine
Description: vaccine inoculation and mixed inoculation

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: SARS-CoV-2 messenger RNA-1273 (Moderna) vaccine
Description: vaccine inoculation and mixed inoculation
Study: NCT05602558

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Aluminium hydroxide adjuvant
Study: NCT05324800

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Curcuma Longa Extract Mixture
Description: 2 times a day, 2 capsule for 1 time, after breakfast/dinner meal, for 8 week

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo group
Description: 2 times a day, 2 capsule for 1 time, after breakfast/dinner meal, for 8 week
Study: NCT04952376

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: SMS delivery of information
Description: Patients are informed via SMS that COVID-19 vaccine doses are available and advised to schedule an appointment. Links to information or phone for scheduling will be provided. Messages mimic the clinic's usual practice of information delivery to patients

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Personalized text message delivery of information
Description: Patients are informed via SMS that COVID-19 vaccine doses are available and advised to schedule an appointment. The SMS message is personalized as a recommendation from the primary care clinician

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Interactive or 2-way SMS delivery of information
Description: This intervention is same as in the Arm 2 using personalized messaging from the PCP. In addition, patients are given interactive or 2-way SMS options to obtain additional information about COVID vaccine and answers to frequently asked questions.